Drug intelligence / Profile preview

cis-[4,5-bis-(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]-piperazin-1-yl-methanone

Development stage
Unknown
Modality
Small Molecules
01

Overview

This compound is a synthetic small molecule with the formula C30H32Cl2N4O3 and a molecular weight of approximately 567.51 g/mol. It is structurally related to the class of compounds known as nutlins—cis-imidazoline derivatives that act as potent antagonists of the MDM2-p53 interaction. By inhibiting MDM2 (mouse double minute 2 homolog), these molecules stabilize and activate p53 tumor suppressor protein function in cells with wild-type TP53 gene status. The drug has been studied primarily as a research tool for probing p53 pathway biology and has not been approved for clinical use or advanced into late-stage clinical trials[1][7][8]. No approved indications or marketed products exist for this specific compound.

Other names
CIS-[4,5-BIS-(4-CHLOROPHENYL)-2-(2-ISOPROPOXY-4-METHOXYPHENYL)-4,5-DIHYD ROIMIDAZOL-1-YL]-PIPERAZIN-1-YL-METHANONE1-{[4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]carbonyl}piperazine[(4S,5R)-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-y](1-piperazinyl)methanonerel-((R,S))-bis(aryl)imidazoline piperazine derivative
02

Targets

MDM2 (Mouse double minute 2 homolog)

Beyond the preview

Go deeper on cis-[4,5-bis-(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]-piperazin-1-yl-methanone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cis-[4,5-bis-(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]-piperazin-1-yl-methanone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call